Skip to main content
Signal8

Hinsch Gylvin Lykke

SEC insider (Form 3/4/5 filer). CIK 0002135139. Director at ProQR Therapeutics N.V. (PRQR). 1 reported Form 4/5 transaction since Sep 2024; latest on Jun 2, 2026. Located in LEIDEN.

Companies Hinsch Gylvin Lykke has filed insider reports for

  • ProQR Therapeutics N.V. (PRQR): Director
Hinsch Gylvin Lykke profile photo

Hinsch Gylvin Lykke

CIK: 0002135139

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ProQR Therapeutics N.V. logo
PRQR

ProQR Therapeutics N.V.

Director

Discretionary Trading P&L

Holdings

Transaction History (1 total)

  • ProQR Therapeutics N.V. logo
    PRQR

    ProQR Therapeutics N.V.

    Jun 2, 2026
    Award

    Share Option (Right to Buy)

    Direct
    14.5K shares-

1-1 of 1